Advances in Age Related Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 May 2024 | Viewed by 7209

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Drug Analysis, Faculty of Medicine, University of Prishtina, 10 000 Prishtina, Kosovo
Interests: nano-drug delivery systems; plant extracts; biological activity; enzyme technology; probiotics
Department of Pharmaceutical Technology and Drug Analysis, Faculty of Medicine, University of Prishtina, 10 000 Prishtina, Kosovo
Interests: proteomics; bioinformatics; nano-drug delivery systems; drug analysis; regulatory affairs; neurodegeneration

Special Issue Information

Dear Colleagues,

Age-related drug delivery is very important in drug development. Both drug delivery performance and various age-related physical, mental and physiological changes can affect drug effectiveness and safety in paediatric and geriatric patients. This Special Issue aims to introduce novel drug delivery strategies in paediatric and geriatric patients, such as novel transdermal, nasal, pulmonary and orally dosage forms that provide consistent, precise, timely and more targeted drug delivery. We invite original research articles and reviews on all aspects of age-related drug delivery highlighting the research currently undertaken in the field of paediatric and geriatric drugs for this Special Issue.

We look forward to receiving your contributions.

Dr. Nunzio Denora
Dr. Mimoza Basholli-Salihu
Dr. Aida Loshaj Shala
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • age-related
  • drug delivery
  • paediatric
  • geriatric
  • formulation
  • personalized medicine

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1665 KiB  
Article
Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2–<7 Years: Results of an Open-Label Randomised Study
by Juliane Münch, Carolin Kloft, Madhi Farhan, Vladislav Fishman, Sining Leng, Hans Martin Bosse and Viviane Klingmann
Pharmaceutics 2023, 15(2), 701; https://doi.org/10.3390/pharmaceutics15020701 - 20 Feb 2023
Cited by 1 | Viewed by 1791
Abstract
This single-centre, open-label, randomised, parallel-group study assessed the acceptability, swallowability, palatability, and safety of film-coated, 3 mm diameter mini-tablets in children aged ≥2–<7 years. In total, 300 participants were randomised (2:2:1:1) to receive a single oral administration of 16 (group A) or 32 [...] Read more.
This single-centre, open-label, randomised, parallel-group study assessed the acceptability, swallowability, palatability, and safety of film-coated, 3 mm diameter mini-tablets in children aged ≥2–<7 years. In total, 300 participants were randomised (2:2:1:1) to receive a single oral administration of 16 (group A) or 32 (group B) mini-tablets with soft food or 16 (group C) or 32 (group D) mini-tablets with water. Children in each group were stratified by age group (2–<3 years; 3–<4 years; 4–<5 years; 5–<6 years; and 6–<7 years). Groups C and D were pooled for statistical analyses. The rates of acceptability (swallowed ≥80% of the mini-tablets with or without chewing), swallowability (swallowed all mini-tablets without chewing or any leftover), and palatability (positive/neutral responses) were ≥80.0%, ≥42.0%, and ≥82.0%, respectively, across the study groups. No marked differences were observed between groups or across age groups. No adverse events or issues of clinical relevance with deglutition were reported. Mini-tablets taken with soft food or water provide a suitable method for administering medicines to children aged ≥2–<7 years. This study was registered in the German Clinical Trial Register (No. DRKS00024617). Full article
(This article belongs to the Special Issue Advances in Age Related Drug Delivery)
Show Figures

Figure 1

Review

Jump to: Research

29 pages, 1484 KiB  
Review
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
by Reeju Amatya, Donghee Lee, Kyoung Ah Min and Meong Cheol Shin
Pharmaceutics 2023, 15(7), 1963; https://doi.org/10.3390/pharmaceutics15071963 - 16 Jul 2023
Cited by 1 | Viewed by 2192
Abstract
Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and [...] Read more.
Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors. Thankfully, to date, there have been accumulating research efforts and, as a result, different classes of potent drug candidates have been discovered. In addition, there have also been various attempts to explore pharmaceutical strategies to improve the druggability of drug candidates. In this review, we provided a brief overview of the drug candidates that have undergone clinical trials. In the latter part, strategies for developing better drugs are discussed. Full article
(This article belongs to the Special Issue Advances in Age Related Drug Delivery)
Show Figures

Graphical abstract

29 pages, 3412 KiB  
Review
Quercetin and Its Nano-Formulations for Brain Tumor Therapy—Current Developments and Future Perspectives for Paediatric Studies
by Aida Loshaj Shala, Ilaria Arduino, Mimoza Basholli Salihu and Nunzio Denora
Pharmaceutics 2023, 15(3), 963; https://doi.org/10.3390/pharmaceutics15030963 - 16 Mar 2023
Cited by 2 | Viewed by 2532
Abstract
The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. [...] Read more.
The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. The current treatment protocol consists of surgery, followed using synthetic drugs and radiation. However, the efficacy of these protocols is associated with side effects, poor prognosis and with a median survival of fewer than two years. Recently, many studies were focused on applying plant-derived products to manage various diseases, including brain cancers. Quercetin is a bioactive compound derived from various fruits and vegetables (asparagus, apples, berries, cherries, onions and red leaf lettuce). Numerous in vivo and in vitro studies highlighted that quercetin through multitargeted molecular mechanisms (apoptosis, necrosis, anti-proliferative activity and suppression of tumor invasion and migration) effectively reduces the progression of tumor cells. This review aims to summarize current developments and recent advances of quercetin’s anticancer potential in brain tumors. Since all reported studies demonstrating the anti-cancer potential of quercetin were conducted using adult models, it is suggested to expand further research in the field of paediatrics. This could offer new perspectives on brain cancer treatment for paediatric patients. Full article
(This article belongs to the Special Issue Advances in Age Related Drug Delivery)
Show Figures

Figure 1

Back to TopTop